- Home
- UHG vs DSGN Comparison
UHG vs DSGN Comparison
Compare UHG & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- DSGN
- Stock Information
- Founded
- UHG 2004
- DSGN 2017
- Country
- UHG United States
- DSGN United States
- Employees
- UHG N/A
- DSGN N/A
- Industry
- UHG Homebuilding
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- DSGN Health Care
- Exchange
- UHG Nasdaq
- DSGN Nasdaq
- Market Cap
- UHG 281.1M
- DSGN 264.4M
- IPO Year
- UHG N/A
- DSGN 2021
- Fundamental
- Price
- UHG $6.10
- DSGN $5.62
- Analyst Decision
- UHG
- DSGN Hold
- Analyst Count
- UHG 0
- DSGN 3
- Target Price
- UHG N/A
- DSGN $7.00
- AVG Volume (30 Days)
- UHG 27.9K
- DSGN 145.2K
- Earning Date
- UHG 11-08-2024
- DSGN 11-07-2024
- Dividend Yield
- UHG N/A
- DSGN N/A
- EPS Growth
- UHG N/A
- DSGN N/A
- EPS
- UHG N/A
- DSGN N/A
- Revenue
- UHG $445,729,916.00
- DSGN N/A
- Revenue This Year
- UHG N/A
- DSGN N/A
- Revenue Next Year
- UHG N/A
- DSGN N/A
- P/E Ratio
- UHG N/A
- DSGN N/A
- Revenue Growth
- UHG 6.19
- DSGN N/A
- 52 Week Low
- UHG $5.09
- DSGN $2.13
- 52 Week High
- UHG $9.48
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- UHG 50.53
- DSGN 48.52
- Support Level
- UHG $5.82
- DSGN $5.32
- Resistance Level
- UHG $6.52
- DSGN $7.77
- Average True Range (ATR)
- UHG 0.48
- DSGN 0.58
- MACD
- UHG -0.02
- DSGN -0.09
- Stochastic Oscillator
- UHG 35.16
- DSGN 14.68
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.